Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07677072

Acronym

LUMINOS

Enrollment

Registered

2026-06-30

Start date

2026-05-15

Completion date

2026-12-01

Last updated

2026-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fragility Fractures, Frailty, Osteoporosis, Postmenopausal Osteoporosis

Keywords

Lumican, Osteoporosis, Fragility, FRAX

Brief summary

Osteoporosis is a major cause of morbidity and fragility fractures in postmenopausal women. Bone mineral density (BMD) alone may not fully reflect fracture risk and skeletal fragility. Lumican, an extracellular matrix proteoglycan involved in collagen organization and musculoskeletal tissue homeostasis, has emerged as a potential biomarker for bone health. This prospective observational study aims to investigate the relationship between serum lumican levels, bone mineral density, muscle strength, and clinical fragility indicators in postmenopausal women. Approximately 100 participants will undergo routine osteoporosis assessment including DEXA, laboratory testing, FRAX evaluation, and handgrip strength measurement. The study will evaluate whether serum lumican levels can identify a hidden fragility phenotype beyond conventional bone mineral density measurements.

Detailed description

This is a prospective, observational, single-center clinical study designed to evaluate serum lumican levels in postmenopausal women undergoing routine osteoporosis assessment. The study will investigate the association of lumican with bone mineral density, handgrip strength, FRAX-based fracture risk, history of falls, and fragility fracture history. No treatment or interventional procedure will be applied. Serum lumican will be measured from venous blood samples, and all other clinical and laboratory data will be collected as part of standard osteoporosis evaluation. The study aims to explore whether lumican may contribute to the identification of fragility risk beyond conventional bone mineral density measurements.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

45 Years to No maximum

Healthy volunteers

Inclusion criteria

Inclusion Criteria: * Female sex * Age 45 years or older * Postmenopausal status * Attendance at the Physical Medicine and Rehabilitation outpatient clinic * Undergoing routine bone mineral density (DEXA) assessment and osteoporosis laboratory evaluation * Ability and willingness to provide written informed consent

Design outcomes

Primary

Measure	Time frame	Description
Serum Lumican Level and Bone Mineral Density Association	Baseline (at study enrollment)	Assessment of the relationship between serum lumican levels and bone mineral density (lumbar spine, total hip, and femoral neck BMD measured by DEXA).

Countries

Turkey (Türkiye)

Contacts

CONTACTDilek Ün Oğuzhanasiltürk, MD

dilekunoguzhan@gmail.com+90 5056367184

PRINCIPAL_INVESTIGATORDilek Ün oguzhanasiltürk, MD

Kanuni Sultan and Süleyman Training Resarch Hospital

Outcome results